Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-960P (RNA, U6 small nuclear 960, pseudogene) is a human pseudogene derived from the highly conserved U6 small nuclear RNA (snRNA) gene[2][5]. U6 snRNA is a crucial non-coding RNA component of the spliceosome, essential for pre-mRNA splicing in eukaryotes[1][3]. However, pseudogenes like RNU6-960P are generally regarded as non-functional variants that lack the capacity to encode functional RNA or protein, typically due to sequence mutations or truncations. Pseudogenes may be transcribed and can influence expression of other genes through regulatory mechanisms such as acting as microRNA (miRNA) decoys or competing for RNA-binding proteins, but most U6 snRNA pseudogenes, including RNU6-960P, have not been demonstrated to perform such functions[4]. There is no evidence to date that RNU6-960P is a viable therapeutic target, nor is it directly implicated in disease. It is mainly of genomic and evolutionary interest, sharing partial sequence homology with the functional U6 snRNA, but does not form part of the active spliceosome machinery[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 960, pseudogene (RNU6-960P).